Canaccord Genuity Maintains a 'Buy' on Teva Pharma (TEVA); A Little Reaction or Side Effect?
Tweet Send to a FriendGet Alerts TEVA Hot Sheet
Price: $39.49 --0%
Rating Summary:
7 Buy, 16 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 11 | New: 13
Rating Summary:
7 Buy, 16 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 11 | New: 13
Trade TEVA Now!
Canaccord Genuity maintains a 'Buy' on Teva Pharma (NASDAQ: TEVA) price target of $52.00.
Analyst, Randall Stanicky, said, "There was admittedly little to get excited about in TEVA’s 2Q results though the stock weakness seemed to reflect higher expectations that we just didn’t see heading into the quarter. Nevertheless, we leave 2Q with a view that’s really unchanged in that: (1) the December 11 (date confirmed) strategic update is a key event that can get the stock moving – and it’s not that far away; (2) progress is and will continue on the repositioning front which included another key hire today; and (3) valuation should provide a support net on numbers that we think are achievable. While the quarter lacked upside, full year was reaffirmed and we make no material P&L changes – nor do we expect much movement around Street numbers."
For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.
Shares of Teva Pharma closed at $38.10 yesterday, with a 52 week range of $35.00-$46.65.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Randall Stanicky, said, "There was admittedly little to get excited about in TEVA’s 2Q results though the stock weakness seemed to reflect higher expectations that we just didn’t see heading into the quarter. Nevertheless, we leave 2Q with a view that’s really unchanged in that: (1) the December 11 (date confirmed) strategic update is a key event that can get the stock moving – and it’s not that far away; (2) progress is and will continue on the repositioning front which included another key hire today; and (3) valuation should provide a support net on numbers that we think are achievable. While the quarter lacked upside, full year was reaffirmed and we make no material P&L changes – nor do we expect much movement around Street numbers."
For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.
Shares of Teva Pharma closed at $38.10 yesterday, with a 52 week range of $35.00-$46.65.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Dollar Tree (DLTR) Beats But Looks Stretched - Jefferies
- Needham & Company Lifts Numbers on Marvell (MRVL) on Solid Results
- Toll Bros. (TOL) Q2 Solid but Not Much Better Than Peers
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ViewRelated Entities
Canaccord Genuity
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
